Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
NCT Number: NCT03520283
This pilot trial studies how well systems support mapping works in guiding self-management in stage I-III colorectal cancer survivors. Systems support mapping helps participants to see complex self-management activities on paper, which makes them more actionable. Behavioral interventions, such as systems support mapping, may help colorectal cancer survivors facilitate self-awareness, create motivation for behavior change, and guide self-management.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Winston-Salem, North Carolina, 27157, United States
PRIMARY OBJECTIVES:
I. To evaluate the feasibility of the systems support mapping (MAP) intervention in colorectal cancer survivors, as characterized by enrollment, intervention adherence, and retention rates.
SECONDARY OBJECTIVES:
I. To evaluate intervention acceptability as characterized by participant ratings.
II. To describe outcome variability to inform future studies. III. To identify multi-level contextual factors influencing self-management (SM).
IV. To qualitatively assess feasibility, acceptability using semi-structured interviews.
V. To examine how study results vary by rural-urban context.
OUTLINE:
Participants complete MAP in-clinic over 60-90 minutes.
After completion of study, participants are followed-up for up to 2 weeks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ancillary studies
Ancillary studies
Complete MAP
Other names: MAP Intervention; System Support Mapping Intervention; MAP
Time frame: Up to 1 year
To be calculated as the percent of eligible participants approached who agree to participate. Will use one-sample tests of negative binomial probabilities and binomial proportions to compare rates of feasibility to hypothesized values. Rates will be summarized using point estimates and 95% confidence intervals.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
To be calculated as the percent of participants who complete the study intervention among those enrolled. Will use one-sample tests of negative binomial probabilities and binomial proportions to compare rates of feasibility to hypothesized values. Rates will be summarized using point estimates and 95% confidence intervals.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
To be calculated as the proportion of participants who complete the study measures among those enrolled. Will use one-sample tests of negative binomial probabilities and binomial proportions to compare rates of feasibility to hypothesized values. Rates will be summarized using point estimates and 95% confidence intervals.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
Descriptive statistics will be used to summarize participant ratings of acceptability of intervention.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
Each item in the scale ranges from 0-5, where 0=not at all true and 5=completely true. Scale is a mean of these items and thus ranges from the same minimum of 0 to the same maximum of 5. A higher score represent higher degree of autonomy.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
Scale is a mean of physical and emotional functional management of chronic disease. Each of which runs from 1 (not at all confident) to 10 (totally confident). A higher score represents a higher degree of confidence in self-efficacy.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
Overall score is based emotional and physical management of symptoms and is converted to a norm-based score that ranges from 0-100. Higher score means more of construct or response of managing symptoms.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
The overall score is based on participant's relatedness to interventionists and is converted to a norm-based score that ranges from 26.6-72.5. Higher score on the HEAL measure means a higher degree of patient-provider connection as assessed by the patient.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
Descriptive statistics (means, standard deviations) will be used to summarize proximal outcomes and change in health outcomes by assessment measure. The primary interest will be in estimating the variance for use in planning future studies. A 4-item questionnaires to assess participants' stress during the intervention at baseline and at two weeks with a difference of both time points. Scoring scale is from 0-4 ( 0 - never and 4 - very often). Scoring range is 0-16 with the higher score indicating higher stress.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
PROMIS instruments contain a fixed number of items from seven PROMIS domains: depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; and ability to participate in social roles and activities. The PROMIS-29, a generic health-related quality of life survey, assesses each of the 7 PROMIS domains with 4 questions. The questions are ranked on a 5-point Likert Scale. There is also one 11-point rating scale for pain intensity. Norm-based scores have been calculated for each domain on the PROMIS measures, so that a score of 50 represents the mean or average of the reference population. A score of 60 means that the person is one standard deviation above the reference population. On symptom oriented domains of PROMIS-29 (anxiety, depression, fatigue, pain interference, and sleep disturbance), higher scores represent worse symptomatology. On the function oriented domains (physical functioning and social role) higher scores represent better functioning.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
Descriptive statistics will be used to summarize proximal outcomes. Participants were asked questions about their health behavior related to their past or present smoking behaviors (i.e. packs per day, last time they smoked) in order to help improve upon the information received to offer support for future studies.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
Will conduct a qualitative content analysis. Qualitative data will be sent to an external vendor to be transcribed. Two internal study team members will double-code at least 10% of coding of transcripts from the semi-structured interviews and resolve any disagreements to ensure that robust and unbiased results are achieved. Will evaluate qualitative and quantitative analyses in a mixed-methods framework for consistency and discrepancies across all analyses to refine the protocol.
Time frame: Up to 1 year
The internal study team will work with collaborators through an iterative process to facilitate a qualitative content analysis of the large quantity of textual MAP data. Will examine all qualitative analyses by urban-rural status as classified using Rural Urban Commuting Area Codes. Qualitative results will be summarized by urban-rural status. Will also compare MAP results by rural-urban status.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
Participant's ability to participate in physical activities (types of activities, intensity, etc.) will be assessed. Descriptive statistics will be used to summarize proximal outcomes. The primary interest will be in estimating the variance for use in planning future studies.
Time frame: Approximately 1.5-2 hours at baseline visit in clinic with a 2-week follow-up 2 weeks later
Participants will assess the use of complementary or alternative therapies use since first diagnosed with cancer. Descriptive statistics will be used to summarize proximal outcomes. The primary interest will be in estimating the variance for use in planning future studies.
Time frame: Up to 1 year
Will conduct a qualitative content analysis. Qualitative data will be sent to an external vendor to be transcribed. Two internal study team members will double-code at least 10% of coding of transcripts from the semi-structured interviews and resolve any disagreements to ensure that robust and unbiased results are achieved. Will evaluate qualitative and quantitative analyses in a mixed-methods framework for consistency and discrepancies across all analyses to refine the protocol.
Time frame: Up to 1 year
Will conduct a qualitative content analysis. Qualitative data will be sent to an external vendor to be transcribed. Two internal study team members will double-code at least 10% of coding of transcripts from the semi-structured interviews and resolve any disagreements to ensure that robust and unbiased results are achieved. Will evaluate qualitative and quantitative analyses in a mixed-methods framework for consistency and discrepancies across all analyses to refine the protocol.
Wake Forest University Health Sciences
Other
Use of Systems Support Mapping to Guide Patient-Driven Self-Management in Rural and Urban Cancer Survivors
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02677389
Breast Diseases, Breast Neoplasms
Madison, Wisconsin, United States
View Trial DetailsNCT06894849
Cancer, Cancer Survivor
Charleston, South Carolina, United States
View Trial DetailsNCT04251299
Cancer Survivor
Albuquerque, New Mexico, United States
View Trial DetailsNCT06809452
Cancer Survivor
Assen, Drenthe, Netherlands
View Trial Details